News
-
Expert smorgasbord offer grows
- 24 Mar 2021
Regulatory advisory panel grows to 21 with addition of former PBAC member Jenny Doust.
Read more -
Costly resub pathways? You asked for it
- 24 Mar 2021
Paying $240,000 to take a year for the PBAC to consider a resubmission for a drug or vaccine deemed to offer high added value doesn’t sound that fast but apparently that’s what industry asked for.
Read more -
BioMarin MD speaks on leadership
- 22 Mar 2021
Kathryn Evans explains how gender diversity at the top is good for business.
Read more -
Patient, doctor PBAC calls fall short
- 22 Mar 2021
Hundreds of submissions appear to have little sway when it comes to positive outcomes.
Read more -
Revlimid exclusivity under threat
- 22 Mar 2021
Court expedites trial for first competitor challenge to BMS’ blood cancer drug.
Read more -
New type of flu vax arrives
- 22 Mar 2021
Seqirus’ cell-based quad vax added to local offering but won’t be reimbursed.
Read more -
Roche boss’ baptism of fire
- 19 Mar 2021
Just months after arriving in Australia, this ‘passionately curious’ leader suddenly found herself on Health Minister Greg Hunt’s speed dial. Found out why.
Read more -
Zimmerman heads for Melbourne
- 19 Mar 2021
CAR-T cell therapy likely to be a focus as parliamentary inquiry holds Melbourne hearings in April.
Read more